Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 29, 2020 (Event date: May 4, 2020 for offering)
Business Overview: A biopharmaceutical company focused on developing cell therapy products, specifically its lead asset CAP-1002 for cardiac conditions.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue, profit, cash flow, or margin data. The only financial figure disclosed relates to a proposed capital raise:
- Proposed Offering Size: Up to $40,000,000 in aggregate offering price.
- Instrument: Common Stock, par value $0.001 per share.
- Program: At-the-market equity offering program via H.C. Wainwright & Co., LLC.
Material Changes and Events
The filing discloses two primary material events:
- Equity Offering: On May 4, 2020, the Company filed a prospectus supplement to sell shares under an existing S-3 Registration Statement. The Company intends to use net proceeds for research and development, manufacturing, working capital, and general corporate purposes.
- Clinical Data Announcement: On April 29, 2020, the Company announced new data regarding six compassionate care cases involving COVID-19 patients treated with its lead asset, CAP-1002, at Cedars-Sinai Medical Center.
Guidance, Outlook, and Risks
Use of Proceeds: The Company reserves the right to reallocate proceeds based on business developments and cannot specify all particular uses with certainty at this time.
Legal Disclaimer: This report does not constitute an offer to sell or a solicitation of an offer to buy shares in jurisdictions where such offer would be unlawful.
Risks/Contingencies: The filing does not explicitly detail new risks beyond the standard regulatory disclaimers regarding the equity offering and the experimental nature of the compassionate use cases.
Investor Verification Checklist
- Verify the final amount of shares sold and actual net proceeds received from the $40 million at-the-market offering.
- Review the full text of the press release (Exhibit 99.1) for specific clinical outcomes of the six COVID-19 compassionate care cases.
- Confirm the status of the S-3 Registration Statement and any subsequent amendments.
- Monitor future filings for the actual allocation of capital raised between R&D, manufacturing, and working capital.